Imunon (NASDAQ:IMNN) Releases Earnings Results, Beats Estimates By $0.07 EPS

Imunon (NASDAQ:IMNN) released its quarterly earnings results on Monday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07, Zacks reports.

Imunon Trading Up 3.7%

IMNN traded up $0.03 on Monday, hitting $0.83. 23,558 shares of the stock traded hands, compared to its average volume of 887,463. Imunon has a 52 week low of $0.64 and a 52 week high of $3.65. The firm has a market capitalization of $12.14 million, a PE ratio of -0.44 and a beta of 1.75. The business has a fifty day moving average price of $0.90 and a two-hundred day moving average price of $0.88.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. D. Boral Capital reissued a “buy” rating and issued a $29.00 price target on shares of Imunon in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Imunon in a research report on Wednesday, March 26th.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.